Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Risk factors for migraine disease progression: a narrative review for a patient-centered approach
Background In individuals with migraine, attacks may increase in frequency, severity, or
both. Preventing migraine progression has emerged as a treatment goal in headache …
both. Preventing migraine progression has emerged as a treatment goal in headache …
Management of chronic migraine
A Hovaguimian, J Roth - Bmj, 2022 - bmj.com
Chronic migraine is a neurologic disorder associated with considerable disability, lost
productivity, and a profound economic burden worldwide. The past five years have seen a …
productivity, and a profound economic burden worldwide. The past five years have seen a …
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice
Objective To incorporate recent research findings, expert consensus, and patient
perspectives into updated guidance on the use of new acute and preventive treatments for …
perspectives into updated guidance on the use of new acute and preventive treatments for …
Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study
Objective To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal
antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment …
antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment …
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre …
Background Many patients who require migraine preventive treatment have not been able to
tolerate or have not responded to multiple previous preventive medications. We aimed to …
tolerate or have not responded to multiple previous preventive medications. We aimed to …
ARISE: a phase 3 randomized trial of erenumab for episodic migraine
Background Calcitonin gene-related peptide plays an important role in migraine
pathophysiology. Erenumab, a human monoclonal antibody that inhibits the calcitonin gene …
pathophysiology. Erenumab, a human monoclonal antibody that inhibits the calcitonin gene …
The American Headache Society position statement on integrating new migraine treatments into clinical practice
American Headache Society - … : The Journal of Head and Face …, 2019 - Wiley Online Library
Objective To provide healthcare professionals with updated guidance in the use of novel
preventive and acute treatments for migraine in adults. Background The principles of …
preventive and acute treatments for migraine in adults. Background The principles of …
Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults
Background Quality clinical trials form an essential part of the evidence base for the
treatment of headache disorders. In 1991, the International Headache Society Clinical Trials …
treatment of headache disorders. In 1991, the International Headache Society Clinical Trials …
Long‐term efficacy and safety of erenumab in migraine prevention: results from a 5‐year, open‐label treatment phase of a randomized clinical trial
Background and purpose Although erenumab has demonstrated significant reduction in
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial
Objective To determine the effect of erenumab, a human anti-calcitonin gene-related peptide
receptor monoclonal antibody, in patients with chronic migraine and medication overuse …
receptor monoclonal antibody, in patients with chronic migraine and medication overuse …